-
RFK Jr. Senate affirmation listening to highlights
Robert F. Kennedy Jr., President Donald Trump’s controversial pick to lead the Department of Health and Human Services, testified Wednesday before a crucial Senate panel, where he faced questions about past vaccine skepticism, his evolving views on abortion and grasp on sprawling federal health programs. Kennedy, 71, appeared first before the Senate Committee on Finance,…
-
UnitedHealthcare names Tim Noel new CEO after Brian Thompson killing
UnitedHealthcare signage is displayed on an office building in Phoenix, Arizona, on July 19, 2023. Patrick T. Fallon | Afp | Getty Images UnitedHealthcare on Thursday tapped company veteran Tim Noel as its new CEO following the targeted killing of its former top executive, Brian Thompson, in Manhattan in December. Noel was the head of…
-
GLP-1s, Brian Thomson killing loom giant at JPM Well being
Jamie Dimon, chief executive officer of JPMorgan Chase & Co., at the Institute of International Finance (IIF) during the annual meetings of the IMF and World Bank in Washington, DC, US, on Thursday, Oct. 24, 2024. Kent Nishimura | Bloomberg | Getty Images San Francisco, famed for its abundance of hoodie-clad tech workers, was overrun…
-
Eli Lilly LLY cuts 2024 income outlook on weight reduction medicine
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker’s…
-
Excessive-cost weight reduction medication enhance vitamin counseling with employers
Packages of weight loss drugs Wegovy, Ozempic and Mounjaro. Picture Alliance | Getty Images A few years ago, when Virta Health founder and CEO Sami Inkinen approached employers about leveraging the company’s nutrition-oriented digital diabetes program for obesity-related weight loss, most companies weren’t ready to commit. Now, more employers are all in on nutritional counseling…
-
Surgeon basic points new advisory
A customer drinks a glass of beer at the Saxton Pub in Austin, Texas, April 5, 2023. Brandon Bell | Getty Images The U.S. surgeon general issued a new advisory warning Friday about the link between alcohol consumption and increased cancer risk, and pushed for policy changes to help reduce the number of alcohol-related cancers.…
-
FDA Zepbound scarcity ends, impacts sufferers, compounding pharmacies
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters The roughly $1,000 monthly price tag of Eli Lilly‘s weight loss drug Zepbound put the blockbuster treatment out of reach for Willow Baillies, 29, whose insurance does not cover it. Baillies,…
-
Danaher had a disappointing 2024. Its path to success subsequent 12 months goes by means of Wall Road
Life sciences firm Danaher has certainly not been an easy stock to own this year. A wave of startups going public on Wall Street would go a long ways toward changing that. Year-to-date performance: down 0.1% Forward price-to-earnings multiple: 27.8 versus a five-year average of 28.8 Our rating: Buy-equivalent 1 Our price target: $305 a…
-
FDA approves Eli Lilly’s weight reduction drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images The Food and Drug Administration on Friday approved Eli Lilly‘s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding…
-
Ozempic faces scrutiny over potential eye situation threat
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. There may be a…
